Vigabatrin Drug Asset Due Diligence Report 2026

This Vigabatrin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Vigabatrin can convert its Small molecule drug profile and GABA-T biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vigabatrin (query alias: vigabatrin)
Modality / target	Small molecule drug; GABA-T; GABA transaminase inhibitors
Highest global status	Approved
Originator	Sanofi
Active developers	Sanofi, ORPHELIA Pharma SAS, Pyros Pharmaceuticals, Inc.

The MCP disease footprint includes Epilepsies, Partial, Seizures, Spasms, Infantile. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2025/03/082665	Phase 4	Not Yet Recruiting	100	Not disclosed
CTR20240280	Phase 4	已完成	57	Not disclosed
CTRI/2022/12/048517	Not Applicable	Not Yet Recruiting	90	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut syndrome (LennoVig): A single center randomized double-blind placebo-controlled trial

Phase 3; n=98; evaluation: Positive. Reported fields: Drop attacks(≥50% reduction) = 8.9 % ; Drop attacks(≥50% reduction) = 51.7 %

Combination Therapy With Vigabatrin and Prednisolone Versus Vigabatrin Alone for Infantile Spasms

Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: death = One death was reported in the vigabatrin group ; Adverse Event: death = One death was reported in the vigabatrin group

The Effect of Vigabatrin on Insulin Sensitivity

Phase 2; n=4; evaluation: not stated. Reported fields: Insulin Sensitivity(Mean) = 6.82 mg/kg FFM/min (Standard Deviation, 1.7); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vigabatrin addresses Epilepsies, Partial, Seizures, Spasms, Infantile. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-03-24	PANTHERx® Rare Selected by Upsher-Smith Laboratories, LLC as Specialty Pharmacy for VIGAFYDE™ (vigabatrin) Oral Solution	Approved	Financial terms not disclosed
2024-10-25	Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals	Approved	Financial terms not disclosed
2021-07-21	ORPHELIA Pharma and Clinigen sign an agreement to supply Kigabeq®	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Stable liquid vigabatrin pharmaceutical composition for oral dosage”. The milestone feed surfaced a patent-application signal described as “Vigabatrin liquid pharmaceutical composition”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO